Global Hemolytic Anemia Market, By Treatment Type (Blood Transfusions, Medicines, Plasmapheresis, Surgery, Blood and Marrow Stem Cell Transplants, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Blood Tests, Biopsy, Urine Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Hemolytic anemia is a type of anemia that occurs when your red blood cells break down or die quicker than your body can replace them with new ones. Hemolytic anemia can be caused by inheriting anemia-causing genetic disorders, infections, or specific drugs. Hemolytic anemia treatment varies based on the origin of the sickness. Blood transfusions, corticosteroid medications, and Rituximab are all possible treatments. Surgery to remove the spleen is recommended in more severe cases.
Data Bridge Market Research analyses that the hemolytic anemia market was valued at USD 309.18 million in 2021 and is expected to reach USD 470.91 million by 2029, registering a CAGR of 5.40% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
Report Metric |
Details |
Forecast Period |
2022 to 2029 |
Base Year |
2021 |
Historic Years |
2020 (Customizable to 2014-2019) |
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
Segments Covered |
Treatment Type (Blood Transfusions, Medicines, Plasmapheresis, Surgery, Blood and Marrow Stem Cell Transplants, Others), Route of Administration (Oral, Parenteral, Others), Diagnosis (Blood Tests, Biopsy, Urine Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) |
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
Market Players Covered |
Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.) |
Market Opportunities |
|
Market Definition
Hemolytic anemia is a disease in which red blood cells (RBCs) are destroyed prematurely and removed from the circulatory system before their life span has expired. Red blood cells, also known as erythrocytes, are disk-shaped structures that transport oxygen from the lungs to the body's organs and assist in the removal of carbon dioxide. The spleen removes red blood cells (RBCs) from the bloodstream after a normal lifespan of 120 days. Bone marrow manufactures red blood cells. Bone marrows cannot create enough RBCs to meet the body's needs in persons with acquired (autoimmune) hemolytic anemia.
Hemolytic Anemia Market Dynamics
Drivers
- Increasing prevalence of iron-deficiency anemia
The rising prevalence of iron-deficiency anemia is estimated to influence the market's growth rate. Along with this, the growing incidences of chronic kidney diseases will influence the market dynamics during the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of hemolytic anemia market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hemolytic anemia market. Additionally, high disposable income and increase in the risk of haemodilution will expand the hemolytic anemia market. Along with this, rising geriatric population and sedentary lifestyle of people will enhance the market's growth rate.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hemolytic anemia market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the hemolytic anemia market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment and diagnosis will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hemolytic anemia market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Hemolytic anemia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Hemolytic Anemia Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of hemolytic anemia in recent months.
Recent Development
- In June 2021, Sandoz announced the launch of the first generic high dose intravenous iron named Ferumoxytol Injection, which is used to treat US patients suffering from iron deficiency anemia. Ferumoxytol, a generic version of AMAG Pharmaceuticals' Feraheme (ferumoxytol injection), is approved to treat IDA in adults with an intolerance to oral iron, a poor response to oral iron, or chronic kidney disease.
Global Hemolytic Anemia Market Scope
The hemolytic anemia market is segmented on the basis of treatment type, route of administration, diagnosis, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Blood Transfusions
- Medicines
- Corticosteroids
- Others
- Plasmapheresis
- Surgery
- Blood and Marrow Stem Cell Transplants
- Others
Route of Administration
- Oral
- Parenteral
- Others
Diagnosis
- Blood Tests
- Biopsy
- Urine Tests
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hemolytic Anemia Market Regional Analysis/Insights
The hemolytic anemia market is analysed and market size insights and trends are provided by country, treatment type, route of administration, diagnosis, end-users and distribution channel as referenced above.
The countries covered in the hemolytic anemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the hemolytic anemia market because of the well-established healthcare infrastructure in this region. Additionally, the growing focus of major key players on novel technology will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to number of population and rising healthcare expenditure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Hemolytic Anemia Market Share Analysis
The hemolytic anemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hemolytic anemia market.
Some of the major players operating in the hemolytic anemia market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd.(Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- AbbVie Inc. (U.S.)
- Fresenius SE & Co. KGaA (Germany)
- Lupin (India)
- ViforPharma Ltd. (Switzerland)
- AMAG Pharmaceuticals (U.S.)
- Akebia Therapeutics, INC. (U.S.)
- CHO-A Pharmaceutical CO., LTD. (South Korea)
- Orion Corporation (Finland)
- Pharmacosmos A/S (Denmark)
- Shield Therapeutics (U.K.)
- Advanz Pharmaceutical (U.K.)
- Alkem Labs (India)
- Zydus Cadila (India)
- Hikma Pharmaceuticals PLC (U.K.)
SKU-